Nasus Pharma Ltd income statement

In fiscal 2025, Nasus Pharma Ltd reported revenue of $1.24bn, operating income of −$4.9m (a -0.4% margin) and net income of −$5.9m, or −$0.72 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Nasus Pharma Ltd: income statement, annual
Fiscal year	2025Dec 2025
Revenue	1,235
Research and development	2
General and administrative	3
Operating income	−5
Interest expense	−0
Net income	−6
Diluted EPS	−$0.72
Diluted shares (average)	8m

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: NSRX vs TRLV INDV vs NSRX NSRX vs PBH

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Nasus Pharma Ltd's SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Nasus Pharma Ltd.